• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.12% Nasdaq Up0.71%

    Lexicon Pharmaceuticals, Inc. (LXRX)

    -NasdaqGS
    1.10 Up 0.03(2.80%) Apr 24, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Lexicon Pharmaceuticals, Inc.
    8800 Technology Forest Place
    The Woodlands, TX 77381
    United States - Map
    Phone: 281-863-3000
    Fax: 281-863-8088
    Website: http://www.lexpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:106

    Business Summary 

    Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase II clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound that has completed Phase II clinical trials to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound that has completed Phase I clinical trials for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Ipsen Pharma SAS; and drug discovery alliance with Bristol-Myers Squibb Company and Genentech, Inc. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Lexicon Pharmaceuticals, Inc.

    Corporate Governance 
    Lexicon Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Lonnel Coats , 50
    Chief Exec. Officer, Pres and Director
    432.00K0.00
    Mr. Jeffrey L. Wade J.D., 50
    Chief Financial Officer and Exec. VP of Corp. & Admin. Affairs
    541.00K0.00
    Dr. Alan J. Main Ph.D., 61
    Exec. VP of CMC and Supply Operations
    463.00K0.00
    Dr. Pablo Lapuerta M.D., 52
    Chief Medical Officer and Exec. VP
    452.00K0.00
    Dr. Robert J. Lefkowitz M.D., 71
    Consultant, Independent Director and Member of Corp. Governance Committee
    80.00KN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders